Clinical data | |
---|---|
Trade names | Zoleptil |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 7–13% (oral)[2] |
Metabolism | N-desmethylation to norzotepine (30-40%)[2] |
Elimination half-life | 13.7–15.9 hours, 12 hours (Norzotepine)[2] |
Excretion | 17% (Urine)[2] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.189.143 |
Chemical and physical data | |
Formula | C18H18ClNOS |
Molar mass | 331.86 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Zotepine is an atypical antipsychotic drug indicated for acute and chronic schizophrenia. It has been used in Germany since 1990 (although it has been discontinued in Germany) and Japan since 1982.
Zotepine is not approved for use in the United States, United Kingdom, Australia, Canada or New Zealand.[3]